论文部分内容阅读
肠促胰素是肠道在进食后分泌的一类激素,胰高糖素样肽1(G LP-1)是主要的肠促胰素,通过葡萄糖依赖的方式促进胰岛素分泌、抑制胰高糖素分泌、延缓胃排空和增加饱腹感等作用维持体内血糖的稳定。本文从G LP-1的生理作用出发,比较传统药物治疗2型糖尿病(T2D M)的局限性,探讨基于肠促胰素机制的药物的优点,如以其独特的作用机制同时作用于T2D M的多个病理生理靶点,在全面有效降低血糖的同时,减少低血糖的发生并减轻体重,安全性和耐受性良好,能改善胰岛β细胞的功能。新近的糖尿病治疗指南已将其列入T2D M的治疗药物。
Prostatins are a class of hormones secreted by the gut after eating. Glucagon-like peptide 1 (G LP-1) is the major incretin that promotes insulin secretion in a glucose-dependent manner and inhibits pancreatic hyperglycemia Hormone secretion, delay gastric emptying and increase satiety and other effects to maintain the stability of the body’s blood sugar. Based on the physiological role of G-LP-1, this article compared the limitations of traditional medicine in the treatment of type 2 diabetes mellitus (T2D M) and explored the advantages of drugs based on the mechanism of the incretin-like mechanism. For example, its unique mechanism of action simultaneously acts on T2D M Of multiple pathophysiological targets, while effectively reducing blood glucose, reduce the incidence of hypoglycemia and reduce body weight, safety and well-tolerated, can improve the function of pancreatic β-cells. Recent guidelines for the treatment of diabetes have been included in the treatment of T2D M drugs.